Mitomycin C (MMC) is one of the most important and commonly-used
anticancer drugs.
The report provides brief overview of
AntiCancer, Inc.
Under the terms of the agreement, Eisai acquires the right of first review concerning the results of the Phase I clinical trials for the novel
anticancer agent APS001, which are scheduled to be conducted in the United States by Anaeropharma Science, and the right of first refusal concerning the licensing of the compound under development.
Also during that span, a continuous flow of
anticancer NAS (New Active Substance) is expected to reach the market.
The companies also expect to enter into an OEM distribution agreement under which Caliper will market and sell certain mouse and cell lines developed by
AntiCancer for use in fluorescent protein-based optical imaging experiments.
GPC Biotech AG is a biopharmaceutical company discovering and developing new
anticancer drugs.
Louis School of Medicine, calls it "a novel transcriptional mechanism that may further enhance the use of rapamycin as an
anticancer agent.
Of the 84 patients who were not given
anticancer drugs such as mitomycin and 5-fluorouracil, five, or 6%, developed a new type of cancer more than five years after their surgery.
The focus of Medicinal Chemistry of
Anticancer Drugs is on the mechanism of action of antitumour drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumour agents, aiming at the rationalization of the action of this type of drugs, which would allow the design of new active structures.
Roya Salehi Qrehvarn, one of the researchers, contrary to the present studies on the delivery of only one
anticancer drug at one time, the new nanocarrier carries and releases two
anticancer drugs with less amount of drug but more effectiveness.
GPC Biotech AG is a biotechnology company discovering and developing new
anticancer drugs.
Although tamoxifen's
anticancer effect levels out at 5 years, there's no question that the drug imparts a residual benefit even after long-term users stop taking it.
